162 results
S-3
EX-1.2
MREO
Mereo Biopharma Group Plc
15 May 24
Shelf registration
4:49pm
to Section 3(b)(i).
(vii) No Guarantee of Placement, Etc. The Company acknowledges and agrees that (A) there can be no assurance that the Agent … pursuant to Section 4(o) for which no waiver is applicable and excluding the date of this Agreement,
(A) a negative assurance letter and the written
S-3
MREO
Mereo Biopharma Group Plc
15 May 24
Shelf registration
4:49pm
and there can be no assurance that the IRS or a court will not take a contrary position.
S-14
As used herein, a “U.S. Holder” is a person that, for U.S … be no assurance regarding our PFIC status for the current year or any particular year in the future because PFIC status is factual in nature, depends
10-Q
2024 Q1
MREO
Mereo Biopharma Group Plc
15 May 24
Quarterly report
4:19pm
agreements for its rare disease or oncology product candidates. Although management continues to pursue these plans, there is no assurance
10-Q
2024 Q1
EX-31.1
MREO
Mereo Biopharma Group Plc
15 May 24
Quarterly report
4:19pm
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
10-Q
2024 Q1
EX-31.2
MREO
Mereo Biopharma Group Plc
15 May 24
Quarterly report
4:19pm
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
8-K
EX-99.1
q8ffr tx1hi
15 May 24
Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:06pm
10-K
293 fztfgs
27 Mar 24
Annual report
5:20pm
10-K
EX-31.1
x5jcez47h
27 Mar 24
Annual report
5:20pm
10-K
EX-31.2
ry4425e6497 k4vyg
27 Mar 24
Annual report
5:20pm
8-K
EX-99.1
sr70z8rddm
27 Mar 24
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
4:08pm
8-K
EX-99.1
r8t4hl2it7qa
8 Jan 24
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
7:08am
6-K
EX-99.1
d6wr6
23 Oct 23
Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update
4:08pm
6-K
ltsp w8sucgv
17 Oct 23
Current report (foreign)
7:01am
6-K
EX-99.1
2r4ing8xwrl 83c4or8
17 Oct 23
Current report (foreign)
7:01am
6-K
EX-99.3
evl6spqh4s76
7 Sep 23
Current report (foreign)
7:37am
6-K
EX-99.1
jdsvquelrc36xkdhwy
5 Jun 23
Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit
4:37pm
6-K
EX-99.1
p9ywb0w rzpf
8 May 23
Current report (foreign)
4:07pm
6-K
EX-99.1
zir43jho
5 May 23
Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market
5:06pm
6-K
c17t62a30s9
27 Apr 23
Current report (foreign)
4:15pm
6-K
xibye1z2cnbfip9
10 Nov 22
Current report (foreign)
4:10pm